deferiprone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4188 30652-11-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • deferiprone
  • deferione
  • ferriprox
a chelating agent with an affinity for ferric ion (iron III) indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes
  • Molecular weight: 139.15
  • Formula: C7H9NO2
  • CLOGP: -0.90
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 40.54
  • ALOGS: 0.29
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 25, 1999 EMA APOTEX EUROPE BV
Oct. 14, 2011 FDA APOPHARMA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Agranulocytosis 264.31 34.48 65 894 23684 53324423
Sickle cell anaemia with crisis 153.81 34.48 31 928 4496 53343611
Neutropenia 80.01 34.48 44 915 159141 53188966
Serum ferritin increased 60.37 34.48 15 944 5549 53342558
Death 34.71 34.48 37 922 357195 52990912

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Agranulocytosis 156.73 30.35 46 763 23431 32489286
Neutropenia 56.50 30.35 38 771 142137 32370580
Sickle cell anaemia with crisis 45.60 30.35 11 798 2598 32510119
Death 45.23 30.35 51 758 382466 32130251
Serum ferritin increased 32.13 30.35 10 799 6069 32506648

Pharmacologic Action:

SourceCodeDescription
ATC V03AC02 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Iron chelating agents
FDA MoA N0000000144 Iron Chelating Activity
FDA EPC N0000175522 Iron Chelator
MeSH PA D002614 Chelating Agents
MeSH PA D007502 Iron Chelating Agents
MeSH PA D064449 Sequestering Agents
CHEBI has role CHEBI:38157 iron chelators
CHEBI has role CHEBI:50267 protective agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Iron overload indication 60737008
beta Thalassemia indication 65959000 DOID:12241

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.54 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG/ML FERRIPROX CHIESI N208030 Sept. 9, 2015 RX SOLUTION ORAL 8703156 Oct. 26, 2029 METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
80MG/ML FERRIPROX CHIESI N208030 April 20, 2018 DISCN SOLUTION ORAL 8703156 Oct. 26, 2029 METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
1GM FERRIPROX CHIESI N212269 May 19, 2020 RX TABLET ORAL 10780055 Oct. 25, 2038 METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
1GM FERRIPROX CHIESI N212269 May 19, 2020 RX TABLET ORAL 10940115 Oct. 25, 2038 METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1GM FERRIPROX CHIESI N021825 July 25, 2019 RX TABLET ORAL April 30, 2024 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
500MG FERRIPROX CHIESI N021825 Oct. 14, 2011 RX TABLET ORAL April 30, 2024 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
100MG/ML FERRIPROX CHIESI N208030 Sept. 9, 2015 RX SOLUTION ORAL April 30, 2024 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
80MG/ML FERRIPROX CHIESI N208030 April 20, 2018 DISCN SOLUTION ORAL April 30, 2024 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
1GM FERRIPROX CHIESI N212269 May 19, 2020 RX TABLET ORAL April 30, 2024 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Deoxyhypusine hydroxylase Enzyme IC50 5.30 CHEMBL

External reference:

IDSource
4031179 VUID
N0000183921 NUI
D07416 KEGG_DRUG
4031179 VANDF
C0043832 UMLSCUI
CHEBI:68554 CHEBI
CHEMBL70927 ChEMBL_ID
D000077543 MESH_DESCRIPTOR_UI
DB08826 DRUGBANK_ID
7456 IUPHAR_LIGAND_ID
6958 INN_ID
2BTY8KH53L UNII
2972 PUBCHEM_CID
11645 RXNORM
117386 MMSL
18035 MMSL
51626 MMSL
d04976 MMSL
007561 NDDF
329482000 SNOMEDCT_US
396011004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Deferiprone HUMAN PRESCRIPTION DRUG LABEL 1 0054-0576 TABLET, COATED 500 mg ORAL ANDA 28 sections
Deferiprone HUMAN PRESCRIPTION DRUG LABEL 1 0054-0711 TABLET, COATED 1000 mg ORAL ANDA 28 sections
FERRIPROX HUMAN PRESCRIPTION DRUG LABEL 1 10122-100 TABLET, FILM COATED 500 mg ORAL NDA 28 sections
FERRIPROX HUMAN PRESCRIPTION DRUG LABEL 1 10122-100 TABLET, FILM COATED 500 mg ORAL NDA 28 sections
FERRIPROX HUMAN PRESCRIPTION DRUG LABEL 1 10122-101 SOLUTION 100 mg ORAL NDA 29 sections
FERRIPROX HUMAN PRESCRIPTION DRUG LABEL 1 10122-103 TABLET, FILM COATED 1000 mg ORAL NDA 28 sections
FERRIPROX HUMAN PRESCRIPTION DRUG LABEL 1 10122-104 TABLET 1000 mg ORAL NDA 28 sections
Deferiprone HUMAN PRESCRIPTION DRUG LABEL 1 51672-4196 TABLET 500 mg ORAL ANDA 31 sections
FERRIPROX HUMAN PRESCRIPTION DRUG LABEL 1 52609-0006 TABLET, FILM COATED 500 mg ORAL NDA 28 sections
FERRIPROX HUMAN PRESCRIPTION DRUG LABEL 1 52609-0007 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
FERRIPROX HUMAN PRESCRIPTION DRUG LABEL 1 52609-4502 SOLUTION 100 mg ORAL NDA 29 sections